Axitinib (Inlyta)

Axitinib at a glance

Axitinib, known by the verified brand Inlyta, is a tyrosine kinase inhibitor. It blocks vascular endothelial growth factor receptors, commonly shortened to VEGF receptors. These receptors help regulate blood-vessel growth. The medicine is taken by mouth with or without food. Brand verification here does not establish Indian availability or approval.

Axitinib may be prescribed alone or with an immune checkpoint medicine such as pembrolizumab or avelumab. Each medicine needs its own safety instructions. The combination can create additional risks, particularly liver problems, and some symptoms may have more than one possible cause.

Common practical concerns include high blood pressure, diarrhoea, tiredness, sore hands and feet, mouth discomfort and a hoarse voice. Regular checks can identify changes that are not obvious from how you feel. Keep a current dose record and your treating hospital's urgent advice details available.

How axitinib works

Tumours need a supply of oxygen and nutrients. VEGF signalling encourages the development of blood vessels that can support tumour growth. Axitinib blocks VEGF receptors 1, 2 and 3, interfering with this process. This is called anti-angiogenic treatment; angiogenesis means the formation of new blood vessels.

The medicine is targeted therapy rather than conventional chemotherapy. It is not itself a checkpoint immunotherapy, although the two types can be used together. Blocking a target does not guarantee a response, and side effects do not measure how well treatment is controlling the cancer.

VEGF signalling also matters in healthy tissues. Its inhibition helps explain blood-pressure changes, protein leaking into the urine, bleeding and slower wound healing. These effects are reasons for monitoring, not signs that everyone will develop a serious problem.

How the team decides whether it is suitable

Your oncologist considers the diagnosis and pathology, previous treatment, overall fitness, other illnesses and the applicable prescribing information. Axitinib selection does not generally depend on one specific tumour mutation test in the way some other targeted medicines do. Other tests may still guide the wider treatment plan.

Tell the team about high blood pressure, heart disease, stroke, blood clots, an aneurysm, bleeding, stomach or bowel disease, liver problems and thyroid disease. Mention recent surgery, dental procedures and wounds that have not healed. These details can alter the treatment choice, starting dose or monitoring.

Partner immunotherapy brings its own considerations, including autoimmune disease and previous immune-related reactions. Do not assume that being suitable for axitinib automatically means every combination is suitable. Ask which medicine is responsible for each part of your treatment plan and what to do if one is paused.

Before treatment starts

Blood pressure should be controlled before the first dose. Your team may arrange home monitoring and review existing blood-pressure medicines. Ask which readings need a call, how often to measure and who will check the record. Use a cuff that fits correctly and ask a nurse or pharmacist to demonstrate the technique.

Baseline checks include thyroid function, liver tests and a urine check for protein. Blood counts, kidney function and other chemistry help assess general health and future changes. European information specifically recommends monitoring haemoglobin or haematocrit, which indicate the amount of red blood cells. These can occasionally rise during treatment and contribute to clot risk.

Pregnancy testing is recommended when pregnancy is possible. Bring a list of all medicines, vitamins, herbal products and non-prescription treatments. Tell the team if another doctor has recently prescribed an antibiotic, antifungal, seizure medicine or blood thinner.

If you are due to have an operation or invasive dental work, arrange a plan with the oncology and procedural teams before treatment begins. Do not keep the appointment secret because the procedure seems minor; the team needs to judge healing and bleeding risks.

How to take axitinib

Dose, timing and food

The usual starting dose in the reviewed labels is 5 mg twice daily, approximately 12 hours apart. It can be taken with or without food. Swallow the tablets whole with water. Do not crush, chew or break them. If swallowing is difficult or you use a feeding tube, ask the oncology pharmacist for a plan; the reviewed Inlyta labels do not provide a home dispersion method.

Axitinib is usually taken every day without a planned weekly break. Choose times you can maintain, and record each dose. If tablet strengths or the number of tablets change, ask the pharmacist to write out the new morning and evening doses. Keep old instructions separate to prevent accidental duplication.

Your prescriber may increase or reduce the dose according to blood pressure and other effects. Examples include an increase to 7 mg and then 10 mg twice daily, or a reduction to 3 mg and then 2 mg twice daily. These changes are prescribed steps, not options to choose at home. A lower starting dose may be required for moderate liver impairment or certain unavoidable interactions.

Dose increases also depend on the regimen. The US label allows consideration at intervals of at least two weeks with avelumab, but at least six weeks with pembrolizumab. These are minimum assessment intervals rather than automatic increases. Do not copy another patient's escalation schedule or increase because you have few symptoms.

Missed doses, vomiting and overdose

If you miss a dose, leave it out and take the next one at the usual time. If you vomit after taking a dose, do not replace it. Never take two doses together to make up for a missed or vomited dose. Repeated vomiting or inability to drink needs advice from the team.

If you accidentally take too much, contact your treating hospital or obtain urgent medical assessment immediately. Keep the pack and a note of the amount and time available. Do not wait for symptoms to appear or try to correct the mistake by changing several later doses yourself.

Storage and handling

Keep tablets safely away from children and retain the original packaging and prescription details. US information specifies storage at 20–25°C (68–77°F), with permitted short excursions to 15–30°C (59–86°F). European information does not require special storage conditions. Follow your supplied pack and ask the pharmacist about hot-weather travel or prolonged heat exposure.

Do not share tablets. Return unused supplies through the pharmacy or treating service, especially when an old strength is no longer part of the plan. Check repeat prescriptions early enough to avoid running out, but do not restart leftover medicine after a treatment pause without authorisation.

Monitoring and checking treatment response

Blood pressure can rise early, sometimes within the first few days. Measure it as instructed even when you feel well; high pressure often has no obvious symptoms. Bring the readings to appointments and report values outside your agreed limits. Do not wait until headaches occur to begin monitoring.

Thyroid tests, liver tests and urine protein checks are repeated during treatment. Kidney function, blood counts and other tests depend on your circumstances. There is no single label timetable suitable for every patient. The team may increase monitoring after a dose change, a new symptom or an abnormal result.

When axitinib accompanies pembrolizumab or avelumab, more frequent liver monitoring may be needed because clinically important enzyme elevations can be more frequent than with either medicine alone. The team must consider both drugs when deciding whether to interrupt treatment and whether immune-suppressing treatment is needed.

Scans and other cancer assessments are arranged separately to judge benefit. Tolerability, test results and response together guide continuation. A temporary pause or reduction is a safety measure and does not automatically mean treatment has stopped working.

Common side effects and practical care

High blood pressure

Take prescribed blood-pressure medicines reliably. Tell the team if dizziness, faintness or unusually low readings develop, especially when axitinib is stopped temporarily: pressure can fall as its effect wears off, and your other medicines may need review. Do not adjust them independently.

A severe headache, chest pain, breathlessness, confusion or a sudden change in vision needs urgent assessment rather than repeated measurements at home. Follow your personalised numerical limits, but do not wait for a particular reading when serious symptoms are present.

Diarrhoea

Record how often stools are loose, whether symptoms wake you at night and whether there is pain, blood or mucus. Take the anti-diarrhoea medicine supplied by your team as directed. Drink regularly unless fluid intake is restricted, and seek help if you cannot replace losses or are passing less urine.

Contact the team if diarrhoea persists, worsens or interferes with drinking. With accompanying immunotherapy, bowel inflammation may need a different treatment from ordinary drug-related diarrhoea. Do not keep increasing over-the-counter remedies or assume every episode is caused by axitinib.

Sore hands and feet

Hand-foot syndrome can cause redness, tenderness, swelling, tingling, thickened skin or blisters on palms and soles. Tell the team early, especially if walking, standing or using your hands becomes painful. Treatment may need a pause or reduction rather than simply stronger pain relief.

Use the moisturiser recommended by your team, wear comfortable footwear and reduce rubbing, prolonged pressure and excessive heat. Avoid picking thickened skin or blisters. Ask for advice before using corn plasters or strong skin-removal products. Small adjustments to work or household tasks can prevent repeated irritation.

Tiredness and thyroid changes

Fatigue may come from the treatment, poor sleep, reduced intake or another treatable problem. Plan rest and manageable activity, and report a significant change. An underactive thyroid can cause tiredness, feeling cold, constipation, weight gain or a deeper voice; an overactive thyroid can cause heat intolerance, weight loss or a racing heartbeat. Blood tests distinguish these possibilities.

If thyroid replacement is prescribed, take it as directed and continue the planned blood checks. Do not assume that all tiredness is inevitable or that a normal thyroid result excludes another cause.

Mouth, appetite and digestive symptoms

A sore mouth, altered taste, nausea or reduced appetite may make eating difficult. Use gentle oral care and prescribed anti-sickness treatment. Softer, less irritating foods and smaller meals may be easier. Ask for dietetic help if weight or intake is falling, and contact the team promptly if mouth pain prevents drinking.

Constipation may also occur. The team can recommend suitable measures after considering pain medicines, hydration and your bowel history. Significant abdominal pain, vomiting or a swollen abdomen should not be managed as simple constipation without assessment.

Hoarse voice and hair changes

Axitinib can change the voice, making it hoarse or quieter. Report a persistent change, particularly with swallowing difficulty or breathing symptoms. A voice change alone does not establish that the cancer has worsened. Hair thinning or changes in appearance may also occur; ask for support if they affect confidence or daily life.

Less common but important side effects

Blood clots and artery problems

Clots can affect veins or arteries. One painful swollen leg may suggest a deep-vein clot. Sudden breathlessness or chest pain can indicate a clot in the lung. Weakness on one side, facial drooping, difficulty speaking or sudden loss of vision may indicate a stroke or another arterial blockage. These symptoms require urgent care.

VEGF-pathway inhibitors can also be associated with an aneurysm, a weakened bulging area of an artery, or a dissection, a tear within its wall. Sudden severe chest, back or abdominal pain, especially with faintness or collapse, is an emergency. Tell the team about any known aneurysm and keep blood pressure well controlled.

Bleeding

Report unusual bruising, recurrent nosebleeds, blood in urine or other unexpected bleeding. Coughing up blood, vomiting blood or material resembling coffee grounds, black tar-like stools or bleeding that will not stop needs urgent assessment. Severe bleeding or faintness requires emergency care.

Do not start aspirin, anti-inflammatory painkillers or a blood thinner yourself. If one is already prescribed, the oncology and prescribing teams should coordinate it; abrupt stopping may also be dangerous.

Heart problems

Heart failure means the heart is not pumping effectively enough. Warning symptoms include new breathlessness, difficulty breathing when lying flat, ankle swelling or rapid weight gain. Chest pain, severe breathlessness or collapse requires emergency help.

The axitinib–avelumab combination has a specific warning about major cardiovascular events. Your team should review cardiovascular risk factors and respond promptly to symptoms. This does not mean every episode of swelling is heart failure, but it should not be dismissed without assessment.

Severe abdominal problems and wound healing

A hole in the stomach or bowel wall, called perforation, or an abnormal connection between structures, called a fistula, can occur. Severe or persistent abdominal pain, fever, vomiting, a swollen abdomen or unusual drainage needs urgent assessment. Do not assume these symptoms are ordinary diarrhoea.

Axitinib may slow wound healing. Tell the team about a wound that opens, leaks, becomes painful or does not heal. Surgery needs a planned interruption: US instructions specify at least two days before elective surgery and at least two weeks after major surgery, with adequate healing before restart. European information specifies at least 24 hours before scheduled surgery and restart based on adequate healing. Your surgeons and oncologist must agree the product-specific plan; do not choose the shortest interval yourself.

Brain symptoms called PRES or RPLS

Posterior reversible encephalopathy syndrome, also called reversible posterior leukoencephalopathy syndrome, is an uncommon serious brain condition. It may cause severe headache, confusion, seizures, sleepiness or visual loss, sometimes with high blood pressure. Obtain emergency care for a seizure, sudden vision loss or major neurological change. The word “reversible” does not make it safe to wait or guarantee recovery.

Kidney and liver problems

Proteinuria means protein is leaking into urine. It may have no early symptoms, so urine testing remains important. New swelling, unusually foamy urine or reduced urine needs review. Severe protein loss or kidney problems can require interruption or stopping treatment.

Liver injury may first appear on blood tests. Yellow skin or eyes, dark urine, persistent nausea, unusual tiredness or right-sided upper-abdominal pain warrants prompt advice. Partner immunotherapy can also cause liver inflammation. The team may need to hold both medicines while investigating; do not restart one independently because the other has been stopped.

Other medicines, supplements and vaccinations

Axitinib levels can be changed by medicines affecting liver enzymes called CYP3A4/5. Strong inhibitors, including some antifungals, antibiotics and antiviral medicines, can increase exposure. Strong inducers, including rifampicin, some seizure medicines and St John's wort, can reduce exposure. US information advises avoiding moderate inducers if possible too. The pharmacist should check the exact drug and arrange alternatives or prescribed dose changes when necessary.

Avoid grapefruit and grapefruit juice because they may increase axitinib levels. Do not assume that taking an interacting medicine several hours apart removes the risk. Check supplements and herbal preparations before starting them, including products marketed for immunity or cancer support.

Have painkillers and anticoagulants checked because bleeding risk matters. Ask about appropriate flu, COVID-19 and travel vaccines. Suitability and timing of live vaccines depend on immune function and the complete treatment history; do not apply an arbitrary waiting period to every patient.

Everyday life during treatment

Build the two doses into a manageable routine and keep a diary of symptoms, blood pressure and prescribed changes. If work shifts or travel cross time zones, ask the pharmacist to help maintain sensible spacing. Carry medicines in their original packaging and plan repeat supplies and access to care before travelling.

Stay active within your comfort level, but adapt exercise if feet are sore or you feel dizzy. Do not drive or operate machinery when fatigue, faintness or visual symptoms make it unsafe. New chest pain or breathlessness is a reason for assessment, not something to exercise through.

Tell dentists and other clinicians about axitinib before procedures. Discuss alcohol if liver tests are abnormal or you feel dehydrated. Treatment can affect sleep, work, intimacy and confidence; practical help and emotional support are legitimate parts of care, not distractions from cancer treatment.

Fertility, contraception, pregnancy and breastfeeding

Axitinib can harm a developing baby. Patients who can become pregnant should have pregnancy status checked before treatment and use effective contraception during treatment and for at least one week after the final dose. US information also advises men with partners who can become pregnant to use effective contraception during treatment and for one week afterwards. Tell the team promptly about a possible pregnancy.

Do not breastfeed during treatment. US instructions specify avoiding breastfeeding for two weeks after the last dose; European information prohibits breastfeeding during treatment without giving the same post-treatment interval. Obtain a written restart plan.

Partner treatments can require much longer precautions. For patients who can become pregnant, pembrolizumab requires contraception for four months after its final dose; avelumab requires at least one month. Their breastfeeding precautions use the same respective intervals. Follow the requirements for the whole regimen rather than stopping precautions after axitinib's shorter interval.

Animal studies suggest axitinib may impair male and female fertility. The effect in an individual person cannot be predicted. Discuss fertility preservation before starting if future parenthood is important, and do not assume reduced fertility means contraception is unnecessary.

After treatment stops or changes

Continue the tests and symptom checks arranged by the team. Blood pressure may fall after an axitinib interruption, so antihypertensive treatment may need reassessment. Do not independently stop or continue an old dose if you are becoming dizzy or readings are low; obtain advice.

Wounds must be assessed before restarting after surgery. Keep the contraception and breastfeeding precautions for all medicines, and remember that immune-related problems from partner treatment may require attention after its last dose. Ask which follow-up belongs to axitinib and which belongs to the wider treatment plan.

Return unused tablets when treatment is permanently stopped. Keep a record of the last dose, major reactions and previous dose changes for future healthcare visits.

Frequently asked questions